Sign In
Buy CERT
$8.10
+0.320 (+4.11%)
At Close: Jul 31, 2026
Certara's Vaccine Simulator™ Accurately Predicted Optimal Timing Between Doses for COVID-19
05:30pm, Friday, 23'rd Jul 2021
Clinical Study Confirms Quantitative Systems Pharmacology (QSP) Prediction, Showcasing the Power of Biosimulation Technology Clinical Study Confirms Quantitative Systems Pharmacology (QSP) Prediction,
Certara Appoints Nancy Killefer and Cynthia Collins as New Independent Board Members
04:30pm, Thursday, 15'th Jul 2021
PRINCETON, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced the appointments of Nancy Killefer and Cynthia Collins to its board of directors, effectiv
Certara to Report Second Quarter 2021 Financial Results on August 5, 2021
04:30pm, Wednesday, 14'th Jul 2021
PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2021
Certara Announces Update of BaseCase Software, the Company's Value Communication Platform
08:00am, Thursday, 08'th Jul 2021
Major Release to Help Life Science Companies Maximize Go-to-Market Impact Major Release to Help Life Science Companies Maximize Go-to-Market Impact
The PMDA enters 8th consecutive year of using Certara's biosimulation software The PMDA enters 8th consecutive year of using Certara's biosimulation software
Certara to Participate in the William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference
08:00am, Thursday, 20'th May 2021
PRINCETON, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery, Chief Executive Officer, and Andrew Schemick, Ch
Expanded capabilities in company's Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges Expanded capabilities in company's Immunogenic
Certara, Inc. (CERT) CEO William Feehery on Q1 2021 Results - Earnings Call Transcript
04:45am, Sunday, 09'th May 2021
Certara, Inc. (CERT) CEO William Feehery on Q1 2021 Results - Earnings Call Transcript
Certara Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Guidance
04:15pm, Thursday, 06'th May 2021
PRINCETON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2021.
Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates Earlier
06:15pm, Tuesday, 04'th May 2021
First-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress First-of-its-kind software predicts likelihood of off-target safety issues that could imp
Certara: Using Computer Modelling To Aid Biopharma R&D
06:01am, Sunday, 25'th Apr 2021
Certara is a midsized developer of software for biosimulation. The company has impressive revenues and a strong business model.
Certara to Report Preliminary First Quarter 2021 Financial Results on May 6, 2021
04:15pm, Thursday, 22'nd Apr 2021
PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that it will release preliminary financial results for the first quarter of 2021 after market close on May 6, 2021.
Certara Announces Closing of Public Offering of Common Stock
03:00pm, Monday, 29'th Mar 2021
PRINCETON, N.J.--(BUSINESS WIRE)--Certara announced the closing of its underwritten public offering of its common stock at a public offering price of $25.00 per share.
Certara Announces Pricing of Public Offering of Common Stock
09:44pm, Wednesday, 24'th Mar 2021
PRINCETON, N.J.--(BUSINESS WIRE)--Certara announced the pricing of its public offering of common stock by certain existing stockholders at a price of $25.00 per share.
Certara Set to Join Russell 1000® Index
10:00am, Thursday, 11'th Mar 2021
PRINCETON, N.J.--(BUSINESS WIRE)--Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it is set to join the Russell 1000® Index.
